CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Fludarabine +4 moredrug
Likely dose
Fludarabine 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00427557
NCT00427557Phase 2Completed
CompareCT.gov

Use of Umbilical Cord Blood Cell in the Preparative Regimen of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

M.D. Anderson Cancer Center·interventional·Posted Jan 29, 2007·Updated May 28, 2012

In Brief

A Phase 2 clinical trial evaluating Fludarabine, Melphalan, and 3 other interventions for Multiple Myeloma and 2 related conditions. Completed, enrolled 31 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if giving umbilical cord blood along with standard stem cells after high-dose chemotherapy will improve the response to a stem cell transplant. The safety of this treatment will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma, Leukemia, Lymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 29, 2007
Enrollment StartOct 1, 2006
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 19.4 years ago

Interventions

Fludarabinedrug

30 mg/m\^2 by vein for 4 Days (Day -10 through Day -7).

Melphalandrug

140 mg/m\^2 by vein for 1 Day (Day -7).

Umbilical Cord Bloodprocedure

1 UCB Unit by vein on Day -5.

Rituximabdrug

375 mg/m\^2 by vein once weekly (Days -7, -1, +7, +14) for 4 Weeks (if appropriate).

Peripheral Blood Stem Cell Infusionother

Infusion of blood stem cells on Day 0.